Public Pharmacy Benefit Manager (PBM) Transparency Report

12/01/2020

Table of Contents for Public PBM Transparency Report

Cover Letter.....3

Definitions of Terms Used in This Report.....4

Transparency Reports, As Submitted by PBMs.....5

COMMERCE DEPARTMENT

Pharmacy Benefit Manager Transparency Report

In 2019, Minnesota enacted Minn. Stat. Chapter 62W to increase visibility into pharmacy benefit management (PBM) practices and pricing as well as to provide important consumer protections. In order to create greater transparency, the Legislature required PBMs to make two transparency reports: one to plan sponsors and one to the Commerce Department. Commerce is required to publish the public data contained in PBM reporting to the agency on its website.

Reporting process

The Department provided all licensed entities instructions and templates for aggregate and claims level data. The Department then provided a draft public reporting template, requesting feedback from PBMs on whether they believe any of the fields constituted trade secret data. The Department received minimal input on that question.

PBMs were required to submit transparency reporting information to the Department by October 1, 2020[1], including aggregate and claims level data. Due to the varying nature of PBM business models and contracts, a given PBM may be responsible for submitting both types of reports (aggregate and claims level), only one type of report, or neither report. A summary of the types of reports received by the Department are shown in the table at right.

Summary of response from PBMs	
Total Licensed PBMs	43
Aggregate Reports Submitted	18[2]
Claims Level Reports Submitted	18
Zero Reports Submitted	5
PBMs not responding to Department	13

The data published in the attached public reports is drawn from the aggregate report submitted by the each PBM, except data that would be considered trade secret under Minn. Stat. § 13.37. As required by law, the public reports do not contain any information such as claims level data that could lead to identification of a plan sponsor, and to further protect plan sponsor identity, the reports do not include the name of the PBMs submitting them.

Data limitations

- PBMs were given instructions regarding units, rounding, and calculated fields, but the Department cannot guarantee compliance with the reporting instructions at this time.
- The Department has posted data as submitted by the PBMs, except in cases where "total" fields were not provided as instructed, in which case the Department performed the simple calculation to produce the total amount. The report notes instances where the Department performed that calculation and where that calculation created an inconsistency with other data submitted by the PBM.
- The data in this report has not been independently audited.
- While the Department provided a data dictionary to each PBM, some PBMs may have relatively small variations in how they calculated amounts based on their own internal definitions of a given term.

[1] Minn. Stat. § 62W.06 sets the annual deadline for reporting as June 1. This year, however, Commerce extended the deadline to October 1 in Regulatory Guidance 20-28 issued May 18, 2020 utilizing authority granted to the Department by the Legislature under Minnesota Session Laws - 2020, Regular Session, chapter 71, article 2, section 12).

[2] 16 PBMs submitted the aggregate report using the prescribed template and 2 PBMs used non-standard forms. The data submitted on non-standard forms did not fully match the fields in the prescribed template and therefore the aggregate reports for these 2 PBMs were not included in the following public transparency reports.

Definitions of terms used in PBM public transparency report

WAC
The aggregate wholesale acquisition cost (WAC) of a given drug from the drug's manufacturer (does not include discounts or rebates).

Net WAC
WAC minus any rebates and other fees paid to the PBM with associated claims.

Rebates
Defined in Minn. Stat. § 62W.02 Subd. 17 as all price concessions paid by a drug manufacturer to a pharmacy benefit manager or plan sponsor, including discounts and other price concessions that are based on the actual or estimated utilization of a prescription drug. Rebates also include price concessions based on the effectiveness of a prescription drug as in a value-based or performance-based contract.

Other fees and payments
Any fees and payments, other than those defined as rebates, associated with the pharmaceutical claims in the given category from any source.

Total Rebates and Other Fees and Payments
Calculated as a sum of *total rebates* and *other fees and payments*

Total Rebates and Other Fees and Payments – Non Plan Sponsor
Total amount of rebates and other fees and payments except those that come directly from plan sponsors

Retained Rebates and Other Fees and Payments – Non Plan Sponsor
Total amount of rebates and other fees and payments except those directly from a plan sponsor that are retained by the PBM as revenue for services provided

Retained Rebates and Other Fees and Payments Percentage – Non Plan Sponsor
Calculated as a ratio of *retained rebates and other fees and payments* to *total rebates and other fees and payments*

Therapeutic Category
The grouping of drugs based on similar characteristics such as chemical structure, mechanism of action, or disease treated. PBMs were instructed use the US Pharmacopeia (USP) classification system and report drug groupings at the category level.

Plan Sponsor
A group purchaser as defined under Minn. Stat. § 62J.03; an employer in the case of an employee health benefit plan established or maintained by a single employer; or an employee organization in the case of a health plan established or maintained by an employee organization, an association, joint board trustees, a committee, or other similar group that establishes or maintains the health plan. This term includes a person or entity acting for a pharmacy benefit manager in a contractual or employment relationship in the performance of pharmacy benefit management. Plan sponsor does not include the Minnesota Department of Human Services.

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 9FXW72IP49

Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	**Lowest**	**Mean**
0%	0%	0%

Totals During Data Period								
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 73,467	$ 545	$ 11,639	$ 12,184	$ 0	$ 0	0%	$ 61,283

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
Anticonvulsants	$ 20,043	$ 18,309
Analgesics	$ 11,704	$ 7,444
Antivirals	$ 9,818	$ 9,589
Skeletal Muscle Relaxants	$ 8,071	$ 6,493
Antidepressants	$ 6,861	$ 6,061
Dermatological Agents	$ 4,231	$ 3,611
Immunological Agents	$ 3,015	$ 2,955
Blood Products and Modifiers	$ 2,373	$ 1,807
Respiratory Tract/ Pulmonary Agents	$ 2,206	$ 1,986
Gastrointestinal Agents	$ 1,453	$ 993

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID FMF2WEILZX

Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.
(b) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors[a]		
Highest	Lowest	Mean
100%		618

Totals During Data Period[b]								
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 548,299	$ 75,625	$ 5,920	$ 81,544	$ 0	$ 0	0%	$ 466,755

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
INSULINS	$ 71,137	$ 32,318
JANUS KINASE (JAK) INHIBITORS	$ 64,521	$ 49,181
ARV CMB-NRTI,N(T)RTI, INTEGRASE INHIBITOR	$ 44,149	$ 41,098
ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST)	$ 35,186	$ 24,143
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	$ 29,833	$ 29,833
ANTIVIRALS, HIV-SPEC, NUCLEOSIDE-NUCLEOTIDE ANALOG	$ 29,336	$ 28,815
ANTIPSYCHOTICS,ATYPICAL,DOPAMINE,& SEROTONIN ANTAG	$ 23,583	$ 23,583
Anticonvulsants	$ 19,874	$ 19,874
Cardiovascular Agents	$ 14,159	$ 14,159
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	$ 12,432	$ 12,432

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID I6OQIKK08O

Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.
(b) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors[a]		
Highest	Lowest	Mean
61%	1%	21%

Totals During Data Period[b]							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 425,994,000	$ 20,211,000	$ 402,745,000	$ 422,975,000	$ 21,314,000	$ 2,289,000	11%	$ 3,013,000

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
Blood Glucose Regulators	$ 52,383,000	$ (3,351,000)
Immunological Agents	$ 51,905,000	$ (1,044,000)
Antivirals	$ 40,491,000	$ (904,000)
Unclassified	$ 39,000,000	$ (725,000)
Respiratory Tract/ Pulmonary Agents	$ 31,122,000	$ 210,000
Central Nervous System Agents	$ 27,602,000	$ 771,000
Antineoplastics	$ 21,957,000	$ 55,000
Antipsychotics	$ 20,635,000	$ 47,000
Dermatological Agents	$ 19,729,000	$ 1,081,000
Anticonvulsants	$ 14,712,000	$ 536,000

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 0PVQ3A42FU

Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
20%	20%	20%

Totals During Data Period							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 86,891,806	$ 16,931,104	$ 908,635	$ 17,839,739	$ 16,931,104	$ 3,386,074	20%	$ 69,052,068

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
IMMUNOLOGICAL AGENTS > IMMUNE SUPPRESSANTS	$ 16,529,302	$ 11,117,514
DERMATOLOGICAL AGENTS > DERMATOLOGICAL AGENTS	$ 7,172,115	$ 5,139,044
BLOOD GLUCOSE REGULATORS > INSULINS	$ 5,901,095	$ 3,206,608
CENTRAL NERVOUS SYSTEM AGENTS > MULTIPLE SCLEROSIS AGENTS	$ 4,399,388	$ 3,781,796
BLOOD GLUCOSE REGULATORS > ANTIDIABETIC AGENTS	$ 3,976,746	$ 2,484,947
ANTINEOPLASTICS > MOLECULAR TARGET INHIBITORS	$ 3,703,101	$ 3,696,170
RESPIRATORY TRACT/PULMONARY AGENTS > RESPIRATORY TRACT AGENTS, OTHER	$ 2,596,825	$ 1,786,029
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) > ESTROGENS	$ 2,544,109	$ 2,433,242
CENTRAL NERVOUS SYSTEM AGENTS > ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES	$ 2,320,971	$ 2,086,461
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS > ANTICOAGULANTS	$ 1,598,487	$ 1,133,962

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID M4N0NRS7OR

Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	**Lowest**	**Mean**
0%	0%	0%

Totals During Data Period							
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 331,803,000	$ 50,594,000	$ 0	$ 50,594,000	$ 50,594,000	$ 0	0%	$ 281,209,000

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
Immunological Agents	$ 67,032,000	$ 56,209,000
Blood Glucose Regulators	$ 41,275,000	$ 24,707,000
Central Nervous System Agents	$ 34,424,000	$ 26,273,000
Respiratory Tract/Pulmonary Agents	$ 26,610,000	$ 19,659,000
Antineoplastics	$ 22,765,000	$ 22,674,000
Antivirals	$ 13,935,000	$ 13,797,000
Blood Products and Modifiers	$ 13,141,000	$ 11,909,000
Dermatological Agents	$ 12,767,000	$ 12,175,000
Antidepressants	$ 8,021,000	$ 8,021,000
Cardiovascular Agents	$ 7,994,000	$ 7,930,000

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID M8KB9Q6GHZ

Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean

Totals During Data Period							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments[a]	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC[a]
$ 26,330,795	$ 738,591	$ 65,809			$ 65,809	8%	

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC[a]
ANALGESICS - ANTI-INFLAMMATORY	$ 5,652,852	
DERMATOLOGICALS	$ 1,989,463	
ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES	$ 1,880,323	
ANTIDIABETICS	$ 1,839,995	
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	$ 1,218,696	
Psychotherapeutic and Neurological Agents - Misc.	$ 1,146,917	
ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS	$ 1,013,044	
ANTIDIABETICS	$ 959,717	
DERMATOLOGICALS	$ 819,791	
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	$ 638,774	

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID NZCD989Z1J

Data Period Jan 2019-Dec 2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	**Lowest**	**Mean**
0%	0%	0%

Totals During Data Period							
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 1,913,000	$ 219,000	$ 8,000	$ 227,000	$ 219,000	$ 0	0%	$ 1,701,000

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
Immunological Agents	$ 523,000	$ 487,000
Analgesics	$ 305,000	$ 268,000
Sleep Disorder Agents	$ 300,000	$ 280,000
Antivirals	$ 231,000	$ 220,000
Anticonvulsants	$ 177,000	$ 151,000
Blood Glucose Regulators	$ 105,000	$ 86,000
Antidepressants	$ 65,000	$ 58,000
Blood Products/Modifiers/Volume Expanders	$ 53,000	$ 43,000
Respiratory Tract/Pulmonary Agents	$ 49,000	$ 33,000
Skeletal Muscle Relaxants	$ 47,000	$ 42,000

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID GB94XMQ2I9

Data Period Jan 2019-Dec 2019

Notes
(a) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
0%	0%	0%

Totals During Data Period[a]							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 509,638	$ 49,925	$ 18,416	$ 68,342	$ 50,353	$ 0	0%	$ 441,296

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
Products Without a USP Category	$ 260,659	$ 258,283
Blood Glucose Regulators	$ 59,984	$ 40,658
Dermatological Agents	$ 47,518	$ 34,138
Immunological Agents	$ 26,386	$ 24,620
Cardiovascular Agents	$ 24,241	$ 16,064
Respiratory Tract/Pulmonary Agents	$ 17,870	$ 8,845
Central Nervous System Agents	$ 13,589	$ 12,995
Gastrointestinal Agents	$ 10,174	$ 7,764
Antidepressants	$ 8,872	$ 6,419
Blood Products and Modifiers	$ 5,534	$ 4,075

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID KABDFCFWND

Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors[a]		
Highest	**Lowest**	**Mean**
100%	0%	50%

Totals During Data Period							
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 363,911,000	$ 10,000	$ 222,000	$ 232,000	$ 232,000	$ 222,000	96%	$ 363,679,000

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
Immunological Agents	$ 80,223,000	$ 80,217,000
Blood Glucose Regulators	$ 49,641,000	$ 49,624,000
Central Nervous System Agents	$ 36,694,000	$ 36,686,000
Respiratory Tract/Pulmonary Agents	$ 28,237,000	$ 28,219,000
Antineoplastics	$ 27,433,000	$ 27,431,000
Antivirals	$ 19,560,000	$ 19,557,000
Blood Products and Modifiers	$ 13,546,000	$ 13,543,000
Dermatological Agents	$ 11,861,000	$ 11,854,000
Cardiovascular Agents	$ 10,746,000	$ 10,700,000
Antidepressants	$ 10,025,000	$ 9,999,000

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID CF4194CK8X

Data Period Jan 2019-Dec 2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
0%	0%	0%

Totals During Data Period								
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments[a]	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 27,308,406	$ 5,482,802	$ 0	$ 0	$ 0	$ 0	0%	$ 21,825,604

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
Immunological Agents	$ 7,625,842	$ 6,228,653
Blood Glucose Regulators	$ 7,285,234	$ 5,508,189
Respiratory Tract/ Pulmonary Agents	$ 2,811,630	$ 2,059,420
Cardiovascular Agents	$ 2,115,267	$ 1,964,480
Antivirals	$ 1,636,800	$ 1,607,760
Central Nervous System Agents	$ 1,375,605	$ 791,751
Blood Products and Modifiers	$ 809,472	$ 703,456
Antimycobacterials	$ 622,100	$ 616,213
Hormonal Agents, Suppressant (Pituitary)	$ 577,099	$ 222,377
Anticonvulsants	$ 413,518	$ 395,335

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 1HQMMW5N

Data Period CY2019

Notes
(a) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
90%	0%	39%

Totals During Data Period[a]							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 688,812,134	$ 96,336,197	$ 15,651,526	$ 111,987,723	$ 107,717,364	$ 41,796,331	39%	$ 576,824,411

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
BLOOD GLUCOSE REGULATORS	$ 90,744,720	$ 49,863,299
ANTINEOPLASTICS	$ 68,564,933	$ 67,855,149
RESPIRATORY TRACT/ PULMONARY AGENTS	$ 67,354,426	$ 52,958,692
ANTIVIRALS	$ 44,585,838	$ 41,238,470
IMMUNOLOGICAL AGENTS	$ 43,054,989	$ 32,365,878
CENTRAL NERVOUS SYSTEM AGENTS	$ 39,650,813	$ 35,305,020
CARDIOVASCULAR AGENTS	$ 39,014,410	$ 35,216,593
ANALGESICS	$ 31,400,574	$ 29,206,601
BLOOD PRODUCTS/ MODIFIERS/ VOLUME EXPANDERS	$ 27,107,338	$ 21,084,291
HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS)	$ 24,325,514	$ 22,419,752

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID SXXXYBREM

Data Period CY2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors[a]		
Highest	Lowest	Mean
100%	0%	76%

Totals During Data Period							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 55,383,050	$ 1,938,087	$ 1,456,779	$ 3,394,866	$ 2,036,112	$ 98,025	5%	$ 51,988,184

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
DIABETIC THERAPY	$ 7,856,680	$ 7,011,045
MISCELLANEOUS	$ 7,783,039	$ 7,721,679
ANTIARTHRITICS	$ 4,693,509	$ 4,551,913
ATARACTICS-TRANQUILIZERS	$ 4,184,464	$ 4,038,675
BRONCHIAL DILATORS	$ 3,780,822	$ 3,612,771
ANTICONVULSANTS	$ 2,306,177	$ 2,193,056
ANTIVIRALS	$ 2,039,775	$ 1,977,586
PSYCHOSTIMULANTS-ANTIDEPRESSANTS	$ 2,019,629	$ 1,843,615
AMPHETAMINE PREPARATIONS	$ 1,971,069	$ 1,897,044
ANTINEOPLASTICS	$ 1,850,928	$ 1,844,997

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID Y8LWDBOA1

Data Period CY2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	**Lowest**	**Mean**
0%	0%	0%

Totals During Data Period							
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 781,634	$ 379,071	$ 0	$ 379,071	$ 0	$ 0	0%	$ 402,564

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
Immunological Agents	$ 271,133	$ 120,914
Sleep Disorder Agents	$ 184,283	$ 184,283
Bulk Chemicals	$ 99,995	$ 99,995
Blood Glucose Regulators	$ 59,759	$ (23,454)
Antineoplastics	$ 40,213	$ 40,213
Hormonal Agents	$ 21,960	$ 15,384
Agents to Treat Blood Disorders	$ 20,771	$ 11,363
Cardiovascular Agents	$ 12,780	$ 12,682
Ophthalmic Agents	$ 7,602	$ 3,531
Respiratory Tract Agents	$ 7,560	$ (29,467)

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID YFEPOHWEP

Data Period CY2019

Notes
(a) As reported by the PBM but doesn't reconcile to other reported data.
(b) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors[a]		
Highest	**Lowest**	**Mean**
25%	0%	20%

Totals During Data Period[b]							
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 124,969	$ 23,331	$ 0	$ 23,331	$ 23,331	$ 9,000	39%	$ 101,638

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
Immune Suppressants	$ 72,437	$ 67,739
Antidiabetic Agents	$ 14,320	$ 12,235
Insulins	$ 10,535	$ 4,955
Dyslipidemics, Other	$ 7,845	$ 7,603
Miscellaneous Therapeutic Agents	$ 3,659	$ 3,621
Respiratory Tract/ Pulmonary Agents	$ 3,145	$ 2,576
Anti-inflammatories, Inhaled Corticosteroids	$ 2,746	$ 2,150
Bronchodilators, Sympathomimetic	$ 2,100	$ 1,667
Ophthalmic Anti-allergy Agents	$ 1,246	$ 1,168
Attention Deficit Hyperactivity Disorder Agents, Amphetamines	$ 931	$ (115)

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID MIFQW92IP

Data Period CY2019

Notes
(a) Totals were calculated by the Department based on data reported by the PBM.

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	Lowest	Mean
75%	0%	5%

Totals During Data Period[a]							
WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
$ 72,793,475	$ 17,097,438	$ 1,879,099	$ 18,976,537	$ 18,976,537	$ 1,017,621	5%	$ 53,816,938

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	WAC	Net WAC
IMMUNOLOGICAL AGENTS	$ 13,339,010	$ 8,134,609
BLOOD GLUCOSE REGULATORS	$ 11,566,295	$ 4,623,735
CENTRAL NERVOUS SYSTEM AGENTS	$ 7,115,713	$ 5,871,952
RESPIRATORY TRACT/ PULMONARY AGENTS	$ 5,731,445	$ 4,527,036
ANTIVIRALS	$ 5,661,592	$ 5,176,501
ANTINEOPLASTICS	$ 5,099,381	$ 5,078,677
DERMATOLOGICAL AGENTS	$ 4,267,591	$ 2,691,673
CARDIOVASCULAR AGENTS	$ 2,515,817	$ 2,398,292
BLOOD PRODUCTS/ MODIFIERS/ VOLUME EXPANDERS	$ 2,466,801	$ 1,835,774
GENETIC OR ENZYME DISORDER: REPLACEMENT, MODIFIERS, TREATMENT	$ 2,383,131	$ 1,997,689

Data for Publication on Commissioner Website - AS REPORTED BY THE PBM

Masked PBM ID 8ANP263BS

Data Period CY2019

Notes

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors		
Highest	**Lowest**	**Mean**
100%	100%	100%

Totals During Data Period							
WAC	**Rebates**	**Other Fees and Payments**	**Total Rebates and Other Fees and Payments**	**Total Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments - Non Plan Sponsor**	**Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor**	**Net WAC**
$ 5,335,368	$ 649,582	$ 0	$ 649,582	$ 649,582	$ 649,582	100%	$ 4,685,786

Top 10 Therapeutic Categories by Spend - Descending Order		
Category	**WAC**	**Net WAC**
ANALGESICS - OPIOID	$ 1,564,463	$ 1,320,554
ANTICONVULSANTS	$ 1,335,388	$ 1,160,998
DERMATOLOGICALS	$ 503,200	$ 495,716
ANTIASTHMATIC AND BRONCHODILATOR AGENTS	$ 277,427	$ 212,144
ANTIDEPRESSANTS	$ 200,753	$ 193,637
ANALGESICS - ANTI-INFLAMMATORY	$ 189,246	$ 189,246
ANTICOAGULANTS	$ 127,649	$ 97,865
MUSCULOSKELETAL THERAPY AGENTS	$ 113,709	$ 113,566
ENDOCRINE AND METABOLIC AGENTS - MISC.	$ 95,258	$ 48,399
ANTIVIRALS	$ 85,939	$ 85,590